Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study
NCT00661804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 416
Last updated 2011-11-11
Summary
Thalassemias are inherited blood disorders that can cause anemia and other health problems. The goal of this study is to collect information on complications of the disease among people who currently have or previously had thalassemia.
Conditions
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Thalassemia Clinical Research Network
collaborator NETWORK -
Carelon Research
lead OTHER
Principal Investigators
-
Ellis Neufeld, MD, PhD · Boston Children's Hospital
-
Janet Kwiatkowski, MD · Children's Hospital of Philadelphia
Eligibility
- Min Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2010-12-31
- Completion
- 2011-06-30
Countries
- United States
- Canada
- United Kingdom
Study Locations
More Related Trials
-
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia
NCT00661726 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512564 ·Status: COMPLETED
-
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
NCT00658385 ·Status: COMPLETED ·Phase: NA
-
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
NCT06655662 ·Status: RECRUITING ·Phase: PHASE1
-
Detection Of β-thalassemia Carriers In Assiut
NCT03822585 ·Status: UNKNOWN ·Phase: NA
-
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
NCT01443312 ·Status: COMPLETED
-
Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Screening
NCT06800495 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Reproductive Capacity and Iron Burden in Thalassemia
NCT02308904 ·Status: COMPLETED ·Phase: NA
-
Long Term Outcomes in β Thalassemia Major
NCT02307786 ·Status: COMPLETED
-
Allograft for Sickle Cell Disease and Thalassemia
NCT02038478 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
NCT01709032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bone Marrow for Hemoglobinopathy Research
NCT00669305 ·Status: COMPLETED
-
Multi-Center Study of Iron Overload: Pilot Study
NCT01114776 ·Status: COMPLETED
-
B-Thalasaemia Trait and Its Possible Cardioprotective Role
NCT02428023 ·Status: UNKNOWN
-
Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia
NCT06210139 ·Status: COMPLETED
-
Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
NCT01129076 ·Status: COMPLETED
-
T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients
NCT00520559 ·Status: COMPLETED
-
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events
NCT00346242 ·Status: COMPLETED ·Phase: PHASE4
-
Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects
NCT00971880 ·Status: COMPLETED
-
Long-term Clinical Study of CN128 in Thalassemia Patients
NCT04614779 ·Status: COMPLETED ·Phase: PHASE2
-
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512226 ·Status: COMPLETED ·Phase: NA
-
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
NCT00000623 ·Status: COMPLETED
-
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
NCT01016093 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
NCT00103753 ·Status: UNKNOWN ·Phase: PHASE4
-
Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
NCT05355766 ·Status: COMPLETED ·Phase: PHASE2